The internal phase 2 trials are now complete (Dep Docetaxel, Dep Cabazitaxel). Interim data from Dep Irinotecan has been announced. Viraleze phase 4 post market trial is complete
We have multiple research agreements with known pharma's AstraZeneca, Chase Sun, Genentech, and Merck
We have a license agreement with AstraZeneca
We have 3 products in the market
We have several molecules in preclinical
We have at least one drug (Dep Gemcitabine) ready to go into human trials
We have SPL 7013 Viral Conjunctivitis ready to be licensed out with a 3rd party
We have an off patent drug of AstraZeneca's tested internally with our improved dendrimer enhanced technology ready to go into clinical trials (the defined period agreed upon by Starpharma and AstraZeneca is well and truly over) AstraZeneca have not taken up this option. The ball is obviously in our court to go forward with it.
We have the internal ADC's and Radiotheranostics programs ready to go forward with 3rd parties
We have a new CEO
Our board has been replenished over the last 3 years
Our Chairman in my opinion will be out sometime this year
The science is proven
WHAT WE NEED KNOW IS EXECUTIONBY OUR LEADER TO GET LICENSING DEALS WITH UPFRONT FEES AND GET REVENUE FROM OUR ON MARKET PRODUCTS,
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)